MRI在神经胶质瘤诊断及预后评估中的应用进展
摘要
<正>近年来,随着高分辨结构成像的飞速发展,脑肿瘤成像及临床管理逐渐走向成熟~([1])。MRI作为极为重要的非侵入性检查方法,对肿瘤的临床干预具有重要的指导作用~([2])。本文拟对常规及特殊MRI方法在胶质瘤诊断、治疗规划以及肿瘤的生长监控等方面的应用进行论述,分析脑结构成像、扩散加权成像(DWI)、磁共振波谱成像(MRS)、灌注加权成像(PWI)等的优势、局限性及尚未解决的难题等。
引文
[1]Kessler AT,Bhatt AA.Brain tumour post-treatment imaging and treatment-related complications.Insights Imaging,2018,9(6):1057-1075.
[2]Kniep H C,Madesta F,Schneider T,et al.Radiomics of brain mri:utility in prediction of metastatic tumor type.Radiology,2018:180946.
[3]Louis DN,Perry A,Reifenberger G,et al.The 2016 World Health Organization Classification of Tumors of the Central Nervous System:a summary.Acta Neuropathol,2016,131(6):803-820.
[4]Bangiyev L,Rossi EMC,Young R,et al.Adult brain tumor imaging:state of the art.Semin Roentgenol,2014,49(1):39-52.
[5]Gupta K,Salunke P.Molecular markers of glioma:an update on recent progress and perspectives.J Cancer Res Clin Oncol,2012,138(12):1971-1981.
[6]Young RJ,Gupta A,Shah AD,et al.Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma.Am JNeuroradiol,2013,34(12):2271-2277.
[7]龚军伟,罗天友,吴少平,等.瘤周水肿区扩散张量成像定量参数在胶质瘤分级中的诊断价值.中国医学影像学杂志,2018,26(2):86-89,93.
[8]Ryoo I,Choi S H,Kim J H,et al.Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging:preliminary correlation study with glioblastoma genetic profiles.PLo S One,2013,8(8):e71704.
[9]Comprehensive genomic characterization defines human glioblastoma genes and core pathways.Nature,2008,455(7216):1061-1068.
[10]Bulik M,Jancalek R,Vanicek J,et al.Potential of MRspectroscopy for assessment of glioma grading.Clin Neurol Neurosurg,2013,115(2):146-153.
[11]Matsumura A,Isobe T,Anno I,et al.Correlation between choline and MIB-1 index in human gliomas.A quantitative in proton MR spectroscopy study.J Clin Neurosci,2005,12(4):416-420.
[12]王莉,孙立新,于学文,等.中国磁共振波谱诊断胶质瘤术后复发与放射性脑损伤.中国医学影像学杂志,2014,22(7):535-539.
[13]Furnari FB,Fenton T,Bachoo RM,et al.Malignant astrocytic glioma:genetics,biology,and paths to treatment.Genes Dev,2007,21(21):2683-2710.
[14]Yip S,Iafrate AJ,Louis DN.Molecular diagnostic testing in malignant gliomas:a practical update on predictive markers.J Neuropathol Exp Neurol,2008,67(1):1-15.
[15]Metaweh NAK,Azab AO,El Basmy AAH,et al.Contrastenhanced perfusion MR imaging to differentiate between recurrent/residual brain neoplasms and radiation necrosis.Asian Pac J Cancer Prev,2018,1 9(4):941-948.
[16]Carrillo JA,Lai A,Nghiemphu PL,et al.Relationship between tumor enhancement,edema,IDH1 mutational status,MGMT promoter methylation,and survival in glioblastoma.Am J Neuroradiol,2012,33(7):1349-1355.
[17]Riemenschneider MJ,Jeuken JW,Wesseling P,et al.Molecular diagnostics of gliomas:state of the art.Acta Neuropathol,2010,120(5):567-584.
[18]Sugahara T,Korogi Y,Tomiguchi S,et al.Posttherapeutic intraaxial brain tumor:the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue.Am J Neuroradiol,2000,21(5):901-909.
[19]Homma T,Fukushima T,Vaccarella S,et al.Correlation among pathology,genotype,and patient outcomes in glioblastoma.J Neuropathol Exp Neurol,2006,65(9):846-854.
[20]Inoue T,Ogasawara K,Beppu T,et al.Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas.Clin Neurol Neurosurg,2005,107(3):174-180.
[21]Goebell E,Paustenbach S,Vaeterlein O,et al.Low-grade and anaplastic gliomas:differences in architecture evaluated with diffusion-tensor MR imaging.Radiology,2006,239(1):217-222.
[22]Labussière M,Idbaih A,Wang XW,et al.All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.Neurology,2010,74(23):1886-1890.
[23]Kong DS,Kim ST,Kim EH,et al.Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas:the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.Am J Neuroradiol,2011,32(2):382-387.
[24]Tomanek B,Iqbal U,Blasiak B,et al.Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging.Neuro Oncol,2012,14(1):53-63.
[25]He T,Smith N,Saunders D,et al.Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6gliomas.J Cell Mol Med,2011,15(4):837-849.
[26]Bette S,Gempt J,Huber T,et al.FLAIR signal increase of the fluid within the resection cavity after glioma surgery:generally valid as early recurrence marker?J Neurosurg,2017,127(2):417-425.
[27]Nakajima T,Kumabe T,Kanamori M,et al.Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography.Neurol Med Chir(Tokyo),2009,49(9):394-401.
[28]Larsen VA,Simonsen HJ,Law I,et al.Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis.Neuroradiology,2013,55(3):361-369.
[2]Kniep H C,Madesta F,Schneider T,et al.Radiomics of brain mri:utility in prediction of metastatic tumor type.Radiology,2018:180946.
[3]Louis DN,Perry A,Reifenberger G,et al.The 2016 World Health Organization Classification of Tumors of the Central Nervous System:a summary.Acta Neuropathol,2016,131(6):803-820.
[4]Bangiyev L,Rossi EMC,Young R,et al.Adult brain tumor imaging:state of the art.Semin Roentgenol,2014,49(1):39-52.
[5]Gupta K,Salunke P.Molecular markers of glioma:an update on recent progress and perspectives.J Cancer Res Clin Oncol,2012,138(12):1971-1981.
[6]Young RJ,Gupta A,Shah AD,et al.Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma.Am JNeuroradiol,2013,34(12):2271-2277.
[7]龚军伟,罗天友,吴少平,等.瘤周水肿区扩散张量成像定量参数在胶质瘤分级中的诊断价值.中国医学影像学杂志,2018,26(2):86-89,93.
[8]Ryoo I,Choi S H,Kim J H,et al.Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging:preliminary correlation study with glioblastoma genetic profiles.PLo S One,2013,8(8):e71704.
[9]Comprehensive genomic characterization defines human glioblastoma genes and core pathways.Nature,2008,455(7216):1061-1068.
[10]Bulik M,Jancalek R,Vanicek J,et al.Potential of MRspectroscopy for assessment of glioma grading.Clin Neurol Neurosurg,2013,115(2):146-153.
[11]Matsumura A,Isobe T,Anno I,et al.Correlation between choline and MIB-1 index in human gliomas.A quantitative in proton MR spectroscopy study.J Clin Neurosci,2005,12(4):416-420.
[12]王莉,孙立新,于学文,等.中国磁共振波谱诊断胶质瘤术后复发与放射性脑损伤.中国医学影像学杂志,2014,22(7):535-539.
[13]Furnari FB,Fenton T,Bachoo RM,et al.Malignant astrocytic glioma:genetics,biology,and paths to treatment.Genes Dev,2007,21(21):2683-2710.
[14]Yip S,Iafrate AJ,Louis DN.Molecular diagnostic testing in malignant gliomas:a practical update on predictive markers.J Neuropathol Exp Neurol,2008,67(1):1-15.
[15]Metaweh NAK,Azab AO,El Basmy AAH,et al.Contrastenhanced perfusion MR imaging to differentiate between recurrent/residual brain neoplasms and radiation necrosis.Asian Pac J Cancer Prev,2018,1 9(4):941-948.
[16]Carrillo JA,Lai A,Nghiemphu PL,et al.Relationship between tumor enhancement,edema,IDH1 mutational status,MGMT promoter methylation,and survival in glioblastoma.Am J Neuroradiol,2012,33(7):1349-1355.
[17]Riemenschneider MJ,Jeuken JW,Wesseling P,et al.Molecular diagnostics of gliomas:state of the art.Acta Neuropathol,2010,120(5):567-584.
[18]Sugahara T,Korogi Y,Tomiguchi S,et al.Posttherapeutic intraaxial brain tumor:the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue.Am J Neuroradiol,2000,21(5):901-909.
[19]Homma T,Fukushima T,Vaccarella S,et al.Correlation among pathology,genotype,and patient outcomes in glioblastoma.J Neuropathol Exp Neurol,2006,65(9):846-854.
[20]Inoue T,Ogasawara K,Beppu T,et al.Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas.Clin Neurol Neurosurg,2005,107(3):174-180.
[21]Goebell E,Paustenbach S,Vaeterlein O,et al.Low-grade and anaplastic gliomas:differences in architecture evaluated with diffusion-tensor MR imaging.Radiology,2006,239(1):217-222.
[22]Labussière M,Idbaih A,Wang XW,et al.All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.Neurology,2010,74(23):1886-1890.
[23]Kong DS,Kim ST,Kim EH,et al.Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas:the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.Am J Neuroradiol,2011,32(2):382-387.
[24]Tomanek B,Iqbal U,Blasiak B,et al.Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging.Neuro Oncol,2012,14(1):53-63.
[25]He T,Smith N,Saunders D,et al.Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6gliomas.J Cell Mol Med,2011,15(4):837-849.
[26]Bette S,Gempt J,Huber T,et al.FLAIR signal increase of the fluid within the resection cavity after glioma surgery:generally valid as early recurrence marker?J Neurosurg,2017,127(2):417-425.
[27]Nakajima T,Kumabe T,Kanamori M,et al.Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography.Neurol Med Chir(Tokyo),2009,49(9):394-401.
[28]Larsen VA,Simonsen HJ,Law I,et al.Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis.Neuroradiology,2013,55(3):361-369.